Table 1.
Patient demographics and baseline characteristics of the two trial populations receiving enteric-coated naproxen (pooled data; safety set).
Fig 1.
SODA pain intensity scores preceding ulcer development stratified by ulcer development at baseline, 1 month, and 3 months of treatment with naproxen.
Data are number of patients. SODA, Severity of Dyspepsia Assessment.
Fig 2.
SODA pain intensity scores of patients who had an ulcer either at the final visit of the study (6 months) or at premature study exit for any other reason or completed the study without ulcer.
Data are number of patients. SODA, Severity of Dyspepsia Assessment.
Table 2.
Proportion of patients with NSAID-associated upper gastrointestinal adverse events under naproxen treatment (n = 426).
Table 3.
Ulcer development under naproxen treatment (n = 426).
Table 4.
Relative risk models including all five high risk factors.
Table 5.
Influence of the number of risk factors on ulcer development (n = 426).